

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 676693

CAS: 156274-19-0

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

1. Company Identification

In Case of Emergency Call:

Decontamination Procedures	Pharmaceutical Resources Branch,(301)-496-8780
Material Safety Data Sheets	Drug Synthesis and Chemistry Branch,(301)-496-8795
Toxicity Data	Toxicology Branch,(301)-496-8777
Additional Information	

2. Chemical Product and Composition

Chemical Name	
Common Name	
Synonyms	
Molecular Weight	281
Molecular Formula	C16H11NO2S
Composition	This material consists solely of 676693
Additional Information	

3. Hazards Identification

RTECS Index	
Summary of Risks	To the best of our knowledge, the toxicological properties of this material have not yet been fully investigated.
Known Carcinogen	This compound is not listed in the OSHA, IARC or NTP literature as a carcinogen or cancer suspect agent.
Medical Conditions Aggravated by Contact	Unknown
Target Organs	The target organs of toxicity are not known at this time.
Relevant Routes of Entry	Inhalation, ingestion, and skin/eye contact.
Acute Effects	The acute effects of exposure to this material in the workplace are not known at this time.
Chronic Effects	The chronic effects of exposure to this material in the workplace are not known at this time.
Eye Contact	The effects of eye contact with this material are unknown.
Skin Contact	The effects of skin contact with this material are unknown.
Inhalation	The effects of inhalation of this material are unknown.
Ingestion	The effects of ingestion of this material are unknown.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 676693

CAS: 156274-19-0

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

Known Hazards None known

Additional Information

4. First Aid Measures

Eye Contact Flush with running water for at least 15 minutes. Assure adequate flushing by separating eyelids with fingers. Consult an ophthalmologist immediately.

Skin Contact Remove contaminated clothing. Flush exposed area with running water for at least 15 minutes. Wash skin with plenty of soap and water. Consult a physician. Chemically decontaminate clothing and launder before reuse.

Inhalation Remove victim promptly to fresh air. Administer artificial respiration if victim is not breathing. If breathing is difficult give oxygen. Consult a physician.

Ingestion If person is conscious wash out mouth with water to remove residual compound. Consult a physician immediately.

Additional Provide supportive treatment. No specific antidote exists.

5. Fire Fighting Measures

LEL Unknown Flash Point Unknown.

UEL Unknown Auto Ignition Temp Unknown

Extinguishing Media Water, carbon dioxide, or dry chemical as appropriate to the surrounding fire.

Explosion Hazard Explosive characteristics of this material are not known to have been investigated.

Special Procedures Evacuate personnel to a safe area. Fire fighters should use protective clothing and a self-contained breathing apparatus. Follow DOT emergency guide number 53 f or solids (or 55 for liquids)(1991 Emergency Response Guidebook, DOT P 5800.5).

Hazardous Combustion Byproducts Thermal decomposition may produce toxic by-products or fumes such as carbon monoxide and carbon dioxide and nitrogen oxides. Since specific products of combustion are unknown, as a precaution, assume they are hazardous.

Additional Information

6. Accidental Release Measures

Evacuate the area. Wear a respirator (or if properly trained, a self-contained breathing apparatus), rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard after use. Avoid raising aerosols by promptly covering the spilled compound with wet paper towels. Pick up material with additional towels, place in a bag or barrel, and hold for waste disposal. After compound pick-up is complete, ventilate area and wash spill site. Dispose of contaminated clean-up materials properly.

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 676693
CAS: 156274-19-0

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

7. Handling and Storage

Special Handling This material is an investigational substance. Hazards associated with exposure to this material are unknown. Handling of solids or solutions should be carried out with extreme care to avoid personal exposure. This material should be handled only by those trained in the handling of potentially hazardous material.

Special Storage None.

Additional Information Wash thoroughly after handling.

8. Exposure Controls and Personal Protection

Goggles Wear chemical safety goggles when handling this material.

Gloves Wear rubber or latex gloves (not polyvinylchloride) when handling this material. Laboratory coat or apron and sleeves are also recommended.

Respirator Wear a NIOSH-MSHA approved respirator. Supplied-air packs could alternatively be used by personnel trained in the use of this equipment.

Safety Station Safety shower and eye wash should be accessible.

Apparel Wear a protective laboratory coat or a Tyvek suit with shoe covers during bulk operations.

Ventilation Operations should be conducted in a chemical fume hood, glove box, or ventilated cabinet equipped with mechanical exhaust to the outside. General room ventilation should meet good laboratory design standards.

Additional Information The personal protective equipment listed above should be worn when handling this material. Consider engineering and operational controls to minimize exposure potential.

9. Physical and Chemical Properties

Characteristics Unknown

Additional Information

10. Stability and Reactivity

Chemical Stability This material is stable under most conditions. Hazardous polymerization is not known to occur.

11. Toxicological Information

Toxicological properties of this compound have not yet been fully investigated

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 676693
CAS: 156274-19-0

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

12. Ecological Information

The ecological impact of this material is not yet known.

13. Disposal Considerations

Disposal Observe all Federal, state, and local laws concerning the disposal of hazardous material or waste.

EPA Hazardous Waste Number None

14. Transportation Information

Shipping of samples of this material should adhere to current regulations.

15. Regulatory Information

All Federal, state, and local regulations should be observed.

16. Other Information

Disclaimer

The information in this document was compiled primarily from secondary sources. The information is believed to be correct and accurate, but no independent verification has been performed. No warranty is expressed or implied with respect to the information contained herein.

M A T E R I A L S A F E T Y D A T A S H E E T

Developmental Therapeutics Program, DCT
National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Boulevard
Rockville, Maryland 20852

NSC 606985

Revision Date: October 5, 1993

SECTION I. MATERIAL IDENTIFICATION

Common Name: NSC 606985

CAS: Not available

Molecular Weight: 442

Molecular Formula: $C_{22}H_{19}N_3O_5 \cdot HCl$

Other Designations: NSC 606985

SECTION II. INGREDIENTS AND HAZARDS

Ingredient Name

Percent

Exposure Limits

NSC 606985

100%

NOT YET ESTABLISHED

Toxicity Data:

In Vitro Activity:

NSC 606985 has been designated as a potent toxin based on its inhibition of cell growth *in vitro*; it shows an $MLGI_{50}$ against cancer cells of $<10^{-7.4}$ molar in the NCI tumor panel screen. As a precaution the compound must be handled as a potent toxin.

In Vivo Activity:

Not yet established.

SECTION III. PHYSICAL DATA

Appearance & Odor:

MP: N/A

BP: N/A

Solubility (%): UNKNOWN

Page 2 of 4

SECTION IV. FIRE AND EXPLOSION DATA

Flash Point: UNKNOWN**Flammability Limits:** LEL %: UNKNOWN**Autoignition Temperature:** UNKNOWN

UEL %: UNKNOWN

Extinguishing Media: Water, carbon dioxide, or dry chemical as appropriate to the surrounding fire.**Unusual Fire or Explosion Hazards:** No unusual fire or explosion hazard is known to exist.**Special Fire-fighting Procedures:** Evacuate personnel to a safe area. Fire fighters should use protective clothing and a self-contained breathing apparatus.**Hazardous Combustion Products:** Thermal decomposition may yield carbon monoxide and other toxic substances. Since specific products of combustion are unknown, as a precaution, they should be assumed to be hazardous.

SECTION V. REACTIVITY DATA

Compound Stability: Stability studies have not yet been carried out.**Chemical Incompatibilities:** Unknown at this time**Conditions To Avoid:** Unknown at this time**Hazardous Decomposition Products:** Unknown at this time.

SECTION VI. HEALTH HAZARD INFORMATION

Summary of Risks: The carcinogenicity and teratogenicity of NSC 606985 are unknown.**Signs & Symptoms of Overexposure:** The effects of overexposure to this drug in the workplace are not known. It is anticipated that acute or chronic overexposure could lead to damage of bone marrow, liver, kidney, lymphoid tissue, GI tract and possibly reproductive organs or could be fatal. NSC 606985 is cytotoxic and will produce severe toxic effects to rapidly dividing tissues upon overexposure.**Acute Effects:** UNKNOWN**Chronic Effects:** UNKNOWN**Primary Entry Routes:** Inhalation, ingestion, and skin and/or eye contact.**Target Organs:** The target organs of toxicity in animals are not known at this time.

M A T E R I A L S A F E T Y D A T A S H E E T

Developmental Therapeutics Program, DCT
National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Boulevard
Rockville, Maryland 20852

NSC 606985

Revision Date: October 5, 1993

Medical Conditions Which May Be Aggravated By Contact: UNKNOWN**For Eye Contact:** Immediately flush eyes with copious amounts of water for at least 15 minutes. Consult an ophthalmologist.**For Skin Contact:** Remove contaminated clothing. Wash skin with plenty of soap and water. Consult a physician. Chemically decontaminate clothing and then launder before reuse or incinerate.**For Inhalation:** Remove victim promptly to clean air. If victim is not breathing, administer artificial respiration. If breathing is difficult give oxygen. Consult a physician.**For Ingestion:** Remove residual drug. Consult a physician. Provide supportive treatment. No specific antidote exists.**SECTION VII. SPILL, LEAK AND DISPOSAL PROCEDURES****Cleanup of Spills/Leaks:**

These should be conducted according to the "DTP (NCI) Generic Safe Handling Procedures for Potent Toxic Drugs" (10/13/92): Evacuate area. Wear self-contained breathing apparatus, rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard after use. Avoid raising aerosols by promptly covering the spilled compound with damp paper towels. Pick up compound with additional towels, place in a bag, and hold for waste disposal. Sodium hypochlorite may degrade NSC 606985 to relatively nontoxic derivatives. Expose the contaminated area to the bleach solution for one hour. Afterwards, first wipe the area with paper towels soaked in bleach solution and then with paper towels wet with water. Ventilate area after compound pick-up and decontamination is complete. Dispose of contaminated clean-up materials properly.

Waste Management/Disposal:

Incineration, at a temperature not less than 1000°C, is the recommended method of disposal. Observe all Federal, state, and local laws concerning the disposal of hazardous material or waste. Dissolve solids in a 10% solution of sodium hypochlorite. Add water miscible organic solvent to drug solutions and then treat with the bleach solution. Contaminated glassware, syringes, wipe-up materials, etc., should also be flushed with the bleach solution to reduce residues of toxic materials.

Page 4 of 4

SECTION VIII. SPECIAL PROTECTION INFORMATION

Personal Protective Equipment:

- Goggles:** Wear chemical safety goggles when handling NSC 606985.
Gloves: Wear rubber or latex gloves, not polyvinylchloride, when handling NSC 606985.
Respirator: Wear NIOSH-MSHA approved respirator.
Other: Wear protective laboratory coat.

Workplace Considerations:

Ventilation: Laboratory operations should be conducted in a chemical fume hood, glove box, or ventilated cabinet equipped with filtered mechanical exhaust to the outside.

Safety Stations: Safety shower and eye bath should be accessible.

The personal protective equipment listed above should be worn at all times when handling NSC 606985. Avoid contact and inhalation. Avoid prolonged or repeated exposure. Wash thoroughly after handling.

SECTION IX. SPECIAL PRECAUTIONS

Storage Segregation: Store in a tightly-closed container, protected from light, at -20°C. In case of hygroscopic compounds, store over drierite. Use of a secondary container is recommended.

Other Precautions: The user should be made aware that NSC 606985 is an investigational substance. It is a highly potent cytotoxic agent. Handling as a solid or a solution should be carried out with extreme care to avoid personal exposure. Hazards associated with exposure to NSC 606985 may as yet be unknown. This material should be handled only by those trained in the handling of potentially hazardous material.

For Non-Emergency Information:

Decontamination Procedures 301-496-8780	Chief, Pharmaceutical Resources Branch
Material Safety Data Sheets 301-496-8795	Project Officer, Drug Synthesis And Chemistry Branch
Toxicity Data 301-496-8777	Chief, Toxicology Branch

The information in this document was compiled primarily from secondary sources. The information is believed to be correct and accurate, but no warranty is expressed or implied.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 268665

CAS: --

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

1. Company Identification

In Case of Emergency Call:

Decontamination Procedures

Pharmaceutical Resources Branch, (301)-496-8780

Material Safety Data Sheets

Drug Synthesis and Chemistry Branch, (301)-496-8795

Toxicity Data

Toxicology Branch, (301)-496-8777

Additional Information

2. Chemical Product and Composition

Chemical Name

Common Name

Synonyms

Molecular Weight

514

Molecular Formula

C₂₁H₂₁N₃O₅Sn

Composition

This material consists solely of 268665

Additional Information

3. Hazards Identification

RTECS Index

Summary of Risks

To the best of our knowledge, the toxicological properties of this material have not yet been fully investigated.

Known Carcinogen

This compound is not listed in the OSHA, IARC or NTP literature as a carcinogen or cancer suspect agent.

Medical Conditions Aggravated by Contact

Unknown

Target Organs

The target organs of toxicity are not known at this time.

Relevant Routes of Entry

Inhalation, ingestion, and skin/eye contact.

Acute Effects

The acute effects of exposure to this material in the workplace are not known at this time.

Chronic Effects

The chronic effects of exposure to this material in the workplace are not known at this time.

Eye Contact

The effects of eye contact with this material are unknown.

Skin Contact

The effects of skin contact with this material are unknown.

Inhalation

The effects of inhalation of this material are unknown.

Ingestion

The effects of ingestion of this material are unknown.

[REDACTED]

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 268665

CAS: --

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

Known Hazards None known

Additional Information

4. First Aid Measures

Eye Contact Flush with running water for at least 15 minutes. Assure adequate flushing by separating eyelids with fingers. Consult an ophthalmologist immediately.

Skin Contact Remove contaminated clothing. Flush exposed area with running water for at least 15 minutes. Wash skin with plenty of soap and water. Consult a physician. Chemically decontaminate clothing and launder before reuse.

Inhalation Remove victim promptly to fresh air. Administer artificial respiration if victim is not breathing. If breathing is difficult give oxygen. Consult a physician.

Ingestion If person is conscious wash out mouth with water to remove residual compound. Consult a physician immediately.

Additional Provide supportive treatment. No specific antidote exists.

5. Fire Fighting Measures

LEL Unknown
UEL Unknown

Flash Point Unknown
Auto Ignition Temp Unknown

Extinguishing Media Water, carbon dioxide, or dry chemical as appropriate to the surrounding fire.

Explosion Hazard Explosive characteristics of this material are not known to have been investigated.

Special Procedures Evacuate personnel to a safe area. Fire fighters should use protective clothing and a self-contained breathing apparatus. Follow DOT emergency guide number 53 f or solids (or 55 for liquids)(1991 Emergency Response Guidebook, DOT P 5800.5).

Hazardous Combustion Byproducts Thermal decomposition may produce toxic by-products or fumes such as carbon monoxide and carbon dioxide and nitrogen oxides. Since specific products of combustion are unknown, as a precaution, assume they are hazardous.

Additional Information

6. Accidental Release Measures

Evacuate the area. Wear a respirator (or if properly trained, a self-contained breathing apparatus), rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard after use. Avoid raising aerosols by promptly covering the spilled compound with wet paper towels. Pick up material with additional towels, place in a bag or barrel, and hold for waste disposal. After compound pick-up is complete, ventilate area and wash spill site. Dispose of contaminated clean-up materials properly.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 268665

CAS: --

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

7. Handling and Storage

Special Handling This material is an investigational substance. Hazards associated with exposure to this material are unknown. Handling of solids or solutions should be carried out with extreme care to avoid personal exposure. This material should be handled only by those trained in the handling of potentially hazardous material.

Special Storage None

Additional Information Wash thoroughly after handling.

8. Exposure Controls and Personal Protection

Goggles Wear chemical safety goggles when handling this material.

Gloves Wear rubber or latex gloves (not polyvinylchloride) when handling this material. Laboratory coat or apron and sleeves are also recommended.

Respirator Wear a NIOSH-MSHA approved respirator. Supplied-air packs could alternatively be used by personnel trained in the use of this equipment.

Safety Station Safety shower and eye wash should be accessible.

Apparel Wear a protective laboratory coat or a Tyvek suit with shoe covers during bulk operations.

Ventilation Operations should be conducted in a chemical fume hood, glove box, or ventilated cabinet equipped with mechanical exhaust to the outside. General room ventilation should meet good laboratory design standards.

Additional Information The personal protective equipment listed above should be worn when handling this material. Consider engineering and operational controls to minimize exposure potential.

9. Physical and Chemical Properties

Characteristics Unknown

Additional Information

10. Stability and Reactivity

Chemical Stability This material is stable under most conditions. Hazardous polymerization is not known to occur.

11. Toxicological Information

Toxicological properties of this compound have not yet been fully investigated

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 268665

CAS: --

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

12. Ecological Information

The ecological impact of this material is not yet known.

13. Disposal Considerations

Disposal Observe all Federal, state, and local laws concerning the disposal of hazardous material or waste.

EPA Hazardous Waste Number None

14. Transportation Information

Shipping of samples of this material should adhere to current regulations.

15. Regulatory Information

All Federal, state, and local regulations should be observed.

16. Other Information

Disclaimer

The information in this document was compiled primarily from secondary sources. The information is believed to be correct and accurate, but no independent verification has been performed. No warranty is expressed or implied with respect to the information contained herein.

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCANTIN INJECTABLE

SAFETY DATA SHEET



GlaxoSmithKline

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material	HYCANTIN INJECTABLE	
Synonyms	HYCANTIN INFUSION 1 MG/3 ML * HYCANTIN INJECTION 1 MG/3 ML * HYCANTIN INJECTION 4 MG/5 ML * TOPOTECAN , FORMULATED PRODUCT * NDC NO. 0007-4200-01 * NDC NO. 0007-4200-05 * NDC NO. 0007-4200-40 * NDC NO. 0007-4200-41 * NDC NO. 0007-4200-42 * NDC NO. 0007-4200-43 * NDC NO. 0007-4200-51 * NDC NO. 0007-4200-55 * NDC NO. 0007-4200-90 * NDC NO. 0007-4201-01 * NDC NO. 0007-4201-05 * NDC NO. 0007-4200-44 * NDC NO. 0007-4201-02 * NDC NO. 0007-4201-11	
Company Name	GlaxoSmithKline, Corporate Environment, Health & Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK	
	UK General Information:	+44-20-8047-5000
	Transport Emergency (EU)	+44-1865-407333
	Medical Emergency	+1-612-221-3999, Ext 221
	Information and Advice:	US number, available 24 hours Multi-language response
	GlaxoSmithKline, Corporate Environment, Health & Safety 2200 Renaissance Blvd, Suite 105 King of Prussia, PA 19406 US	
	US General Information:	+1-888-825-5249
	Transport Emergency (non EU)	+1-703-527-3887
		US number, available 24 hours Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS RN	Percentage
TOPOTECAN	119413-54-6	< 10
NON-HAZARDOUS INGREDIENTS	Unassigned	>90

3. HAZARDS IDENTIFICATION

Fire and Explosion	This product is classified as non-flammable.
Health	Exposure might occur via skin; eyes; ingestion. Caution - Potent pharmaceutical agent. May cause cancer. May produce adverse effects on the development of human offspring. Possible effects of overexposure in the workplace include: nausea; vomiting; diarrhoea; bone marrow toxicity. Health effects information is based on hazards of components.

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCAMTIN INJECTABLE

Environment

No information is available about the potential of this product to produce adverse environmental effects.

4. FIRST-AID MEASURES

Ingestion

Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

Inhalation

Physical form suggests that risk of inhalation exposure is negligible.

Skin Contact

Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Eye Contact

Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS**Medical Treatment**

Medical treatment in cases of overexposure should be treated as an overdose of a cytotoxic agent.

Medical Conditions Caused or Aggravated by Exposure

None for occupational exposure.

Health Surveillance Procedures

The need for pre-placement and periodic health surveillance must be determined by risk assessment. Following assessment, if the risk of exposure is considered significant then exposed individuals should undergo appropriate health surveillance that may include symptom enquiry, clinical examination and monitoring of lead organ effects (e.g. full blood counts). In the event of overexposure, individuals should receive post exposure health surveillance focused on the most likely health effects (e.g. full blood counts).

Antidotes

No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards

Not expected for the product, although the packaging is combustible.

Extinguishing Media

Water is recommended for fires involving packaging.

Special Firefighting Procedures

For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products

Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions

For all spills, isolate the spill area, restrict access, post the area for a carcinogen and immediately implement emergency procedures for cleanup and control of occupational carcinogens. Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions

Do not allow this material to enter surface drainage systems, sewers and poorly ventilated areas.

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCAMTIN INJECTABLE

Clean-up Methods

Spread an inert absorbent on the spill and place in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures

Surfaces should be decontaminated so that potential exposures do not exceed the hygiene guide specified in Section 8 of this SDS. The pH of the collected wash waters should be adjusted using base, such as sodium hydroxide, to a pH greater than 8; commercial bleach solution, containing approximately 5% hypochlorite, should then be added to the waste water. Microgram levels of surface contamination can be visualised using ultraviolet light.

7. HANDLING AND STORAGE

HANDLING**General Requirements**

Isolation or enclosure is recommended to control exposure to this material.

STORAGE

The recommended temperature for storage is 15-30 °C.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

INGREDIENT

TOPOTECAN

GSK Occupational Hazard Category

4

GSK Occupational Exposure Limit

0.03 MCG/M3 (8 HR TWA)

CARCINOGEN, REPRODUCTIVE HAZARD, HIGHLY POTENT

ENGINEERING CONTROLS**Containment**

Open handling may result in overexposure. Consider use of enclosures.

Administrative

Entry to the working area should be controlled.

PERSONAL PROTECTIVE EQUIPMENT**Eye Protection**

Wear approved safety glasses with side shields if eye contact is possible.

Gloves

The selection of gloves for a specific activity must be based on the material's properties and on possible permeation and degradation that may occur under the circumstances of use. Glove selection must take into account any solvents and other hazards present. Potential allergic reactions can occur with certain glove materials (e.g. Latex) and therefore these should be avoided. Care must be exercised if no data are available and further guidance should be sought from your local safety department. Glove selection must take into account any solvents and other hazards present.

Respirators

Respiratory protective equipment (RPE) is not required for normal handling of this material.

Other Equipment or Procedures

Wear appropriate clothing to avoid skin contact.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance**Physical Form**

Lyophilised powder.

pH of Aqueous Solutions

3

10. STABILITY AND REACTIVITY

Stability

This product is expected to be stable.

Conditions to Avoid

None for normal handling of this product.

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCAMTIN INJECTABLE

11. TOXICOLOGICAL INFORMATION

Oral Toxicity	Toxicity might occur following ingestion.
Inhalation Toxicity	No studies have been conducted.
Skin Effects	Irritation is not expected following direct contact.
Eye Effects	Irritation is not expected following direct contact with eyes.
Target Organ Effects	Adverse effects might occur in the following organ(s) following overexposure: bone marrow and formation of blood cells.
Sensitisation	Potential for inducing allergic reactions via the dermal or respiratory route is not known.
Genetic Toxicity	Known or probable human mutagen.
Carcinogenicity	Contains a component listed as a carcinogen by: (GSK). No components are listed as carcinogens by: (IARC); (NTP); (US OSHA).
Reproductive Effects	Contains components which have been classified as: Known or presumed to cause toxicity in developing human offspring. Known or presumed to impair fertility in human females.
Pharmacological Effects	This preparation contains ingredient(s) with the following activity: a cytotoxic agent.
Other Adverse Effects	Overexposure in the workplace might have the following effects: reduced white blood cell count; nausea; diarrhoea; vomiting; fatigue.

12. ECOLOGICAL INFORMATION

*** Summary** No information is available about the potential of this product to produce adverse environmental effects. This material contains an active pharmaceutical ingredient that has been tested and which may be harmful if released directly to the environment. Consult the MSDS of the active ingredient for specific information about potential environmental effects. Appropriate precautions should be taken to limit release of this material to the environment. Local regulations and procedures should be consulted prior to environmental release.

Specific information on the active pharmaceutical ingredient is provided below.

ECOTOXICITY

Aquatic

* Microtox

Microtox is a general toxicity test which utilizes a sensitive marine photo bacteria as the test species. This material contains an active pharmaceutical ingredient that is not toxic to these microorganisms.

EC50: 102 mg/L, 15 Minutes

* Daphnid

This material contains an active pharmaceutical ingredient that is harmful to daphids.

EC50: 61.8 mg/L, 48 Hours, Daphnia magna, Static test

* Fish

This material contains an active pharmaceutical ingredient that is harmful to fish.

Adult Pimephales promelas, fathead minnow

EC50: 45.7 mg/L, 96 Hours, Static test

Adult Pimephales promelas, fathead minnow

NOEL: 25 mg/L, 96 Hours, Static test

MOBILITY

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCAMTIN INJECTABLE

- * **Solubility** This material contains an active pharmaceutical ingredient that for environmental fate predictions has solubility in water.
- * **Adsorption** This material contains an active pharmaceutical ingredient that is not likely to adsorb to sludge or biomass if released directly to the environment.
Sludge Biomass 2.28 Measured
Distribution Coefficient
(log Kd):
- * **Partitioning** This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

PERSISTENCE/DEGRADATION

- * **Hydrolysis** This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water. Hydrolysis is unlikely to be a significant depletion mechanism.
Half-Life, Neutral: 35 Years, Measured
- * **Photolysis** This material contains an active pharmaceutical ingredient that has been shown to be chemically unstable in water when exposed to light. Aqueous photolysis may be a significant depletion mechanism.
Half-Life, Aqueous: 2.51 Minutes, Measured
- * **Biodegradation** This material contains an active pharmaceutical ingredient that is not readily biodegradable (as defined by 1993 OECD Testing Guidelines).
Aerobic - Ready
Percent Degradation: 0 %, 28 days, Batch activated sludge (BAS), Residential sludge

13. DISPOSAL CONSIDERATIONS

- Disposal Recommendations** Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used. The recommended method of disposal is incineration.
- Regulatory Requirements** Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Technical Name HYCAMTIN INJECTABLE
Proper Shipping Name Medicine, solid, toxic, nos
(HYCAMTIN INJECTABLE)
UN Number UN 3249
Class/Division 6.1
Packing Group III
Risk Label(s) Class 6.1 Toxic



SDS Number 1283


Approved/Revised 02-Feb-2005

Version 19

Material HYCANTIN INJECTABLE

International Air Transport (IATA Requirements)

UNMD Number ID 8000
Proper Shipping Name/Description Consumer Commodity
ICAO/IATA Class/Division 9
Subsidiary Risk None
Packing Group Not applicable (use packing instruction 910).
Hazard Label(s) Class 9

**Limited Quantities**

Quantities equal to or less than 0.5 kg per inner packaging are not subject to the full packaging and labelling requirements, although the appropriate shipping papers will be required.

International Maritime Transport (IMDG Requirements)

UN Number UN 3249
Proper Shipping Name/Description Medicine, solid, toxic, nos
IMO Class/Division 6.1
Subsidiary Risk None
Packing Group III
Class Label(s) Class 6.1 Toxic



Marine Pollutant Status Not listed

Limited Quantities

Quantities equal to or less than 3 kg per inner packaging are not subject to the full packaging and labelling requirements, although the appropriate shipping papers will be required.

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCANTIN INJECTABLE

US Domestic Transport (DOT Requirements)

Proper Shipping Name	Consumer Commodity, ORM-D
DOT Hazard Class/Division	ORM-D
UN/NA Number	Not applicable.
Packing Group	Not applicable
US Emergency Response Guide Number	151
Quantity Limitations	Quantities equal to or less than 0.25 kg per inner packaging are not subject to the full packaging and labelling requirements, although the appropriate shipping papers will be required.

European Ground Transport (ADR/RID Requirements)

Classification and Labelling	Not subject to ADR, see SP 601.
-------------------------------------	---------------------------------

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

*** EU Classification and Labelling**

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

Safety Phrase(s)	S23 - Do not breathe . S25 - Avoid contact with eyes. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S29 - Do not empty into drains. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S38 - In case of insufficient ventilation, wear suitable respiratory equipment. S53 - Avoid exposure - obtain special instructions before use. S60 - This material and/or its container must be disposed of as hazardous waste.
-------------------------	---

US OSHA Standard (29 CFR Part 1910.1200)

Classification	This product is classified as hazardous according to the OSHA Hazard Communication Standard.
-----------------------	--

Other US Regulations

TSCA Status	Exempt
--------------------	--------

16. OTHER INFORMATION

References	GSK Hazard Determination
-------------------	--------------------------

Date Approved/Revised 02-Feb-2005

SDS Version Number 19

SDS Sections Updated

Sections
ECOLOGICAL INFORMATION

Subsections
Activated Sludge Respiration
Adsorption
Algal
Algal Degradation
Bioaccumulation
Biodegradation
Daphnid

SDS Number 1283

Approved/Revised 02-Feb-2005

Version 19

Material HYCAMTIN INJECTABLE

SDS Sections Updated**Sections**

ECOLOGICAL INFORMATION

Subsections

Distribution

Earthworm

Ecotoxicity

Fish

Hydrolysis

Microbial Growth Inhibition

Microtox

Mobility

Other Adverse Effects

Other Species - Aquatic

Other Species - Terrestrial

Partitioning

Persistence/Degradation

Photolysis

Solubility

Summary

Volatility

REGULATORY INFORMATION

TRANSPORT INFORMATION

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 259968

CAS: 64755-14-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

1. Company Identification

In Case of Emergency Call:

Decontamination Procedures	Pharmaceutical Resources Branch,(301)-496-8780
Material Safety Data Sheets	Drug Synthesis and Chemistry Branch,(301)-496-8795
Toxicity Data	Toxicology Branch,(301)-496-8777
Additional Information	

2. Chemical Product and Composition

Chemical Name	BOUVARDIN (9CI)
Common Name	
Synonyms	
Molecular Weight	773
Molecular Formula	C40H48N6O10
Composition	This material consists solely of 259968
Additional Information	

3. Hazards Identification

RTECS Index	
Summary of Risks	To the best of our knowledge, the toxicological properties of this material have not yet been fully investigated.
Known Carcinogen	This compound is not listed in the OSHA, IARC or NTP literature as a carcinogen or cancer suspect agent.
Medical Conditions Aggravated by Contact	Unknown
Target Organs	The target organs of toxicity are not known at this time.
Relevant Routes of Entry	Inhalation, ingestion, and skin/eye contact.
Acute Effects	The acute effects of exposure to this material in the workplace are not known at this time.
Chronic Effects	The chronic effects of exposure to this material in the workplace are not known at this time.
Eye Contact	The effects of eye contact with this material are unknown.
Skin Contact	The effects of skin contact with this material are unknown.
Inhalation	The effects of inhalation of this material are unknown.
Ingestion	The effects of ingestion of this material are unknown.

[REDACTED]

Developmental Therapeutics Program, National Cancer Institute

NSC: 259968

Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

CAS: 64755-14-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

Known Hazards

TOX IVP

Additional Information

Toxic (TOX) - Avoid all contact. Use proper engineering controls and personal protective equipment when handling.

4. First Aid Measures

Eye Contact Flush with running water for at least 15 minutes. Assure adequate flushing by separating eyelids with fingers. Consult an ophthalmologist immediately.

Skin Contact Remove contaminated clothing. Flush exposed area with running water for at least 15 minutes. Wash skin with plenty of soap and water. Consult a physician. Chemically decontaminate clothing and launder before reuse.

Inhalation Remove victim promptly to fresh air. Administer artificial respiration if victim is not breathing. If breathing is difficult give oxygen. Consult a physician.

Ingestion If person is conscious wash out mouth with water to remove residual compound. Consult a physician immediately.

Additional Provide supportive treatment. No specific antidote exists.

5. Fire Fighting Measures

LEL Unknown Flash Point Unknown

UEL Unknown Auto Ignition Temp Unknown

Extinguishing Media Water, carbon dioxide, or dry chemical as appropriate to the surrounding fire.

Explosion Hazard Explosive characteristics of this material are not known to have been investigated.

Special Procedures Evacuate personnel to a safe area. Fire fighters should use protective clothing and self-contained breathing apparatus. Follow DOT emergency guide number 53 f or solids (or 55 for liquids)(1991 Emergency Response Guidebook, DOT P 5800.5).

Hazardous Combustion Byproducts Thermal decomposition may produce toxic by-products or fumes such as carbon monoxide and carbon dioxide and nitrogen oxides. Since specific products of combustion are unknown, as a precaution, assume they are hazardous.

Additional Information

6. Accidental Release Measures

Evacuate the area. Wear a respirator (or if properly trained, a self-contained breathing apparatus), rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard after use. Avoid raising aerosols by promptly covering the spilled compound with wet paper towels. Pick up material with additional towels, place in a bag or barrel, and hold for waste disposal. After compound pick-up is complete, ventilate area and wash spill site.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 259968

CAS: 64755-14-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

Dispose of contaminated clean-up materials properly.

7. Handling and Storage

Special Handling

This material is an investigational substance. Hazards associated with exposure to this material are unknown. Handling of solids or solutions should be carried out with extreme care to avoid personal exposure. This material should be handled only by those trained in the handling of potentially hazardous material.

Special Storage

Freeze (FRZ) between -18 and -22 degrees Celcius

Additional Information

Wash thoroughly after handling.

8. Exposure Controls and Personal Protection

Goggles

Wear chemical safety goggles when handling this material.

Gloves

Wear rubber or latex gloves (not polyvinylchloride) when handling this material. Laboratory coat or apron and sleeves are also recommended.

Respirator

Wear a NIOSH-MSHA approved respirator. Supplied-air packs could alternatively be used by personnel trained in the use of this equipment.

Safety Station

Safety shower and eye wash should be accessible.

Apparel

Wear a protective laboratory coat or a Tyvek suit with shoe covers during bulk operations.

Ventillation

Operations should be conducted in a chemical fume hood, glove box, or ventilated cabinet equipped with mechanical exhaust to the outside. General room ventilation should meet good laboratory design standards.

Additional Information

The personal protective equipment listed above should be worn when handling this material. Consider engineering and operational controls to minimize exposure potential.

9. Physical and Chemical Properties

Characteristics

Unknown

Additional Information

10. Stability and Reactivity

Chemical Stability

This material is stable under most conditions. Hazardous polymerization is not known to occur.

11. Toxicological Information

In-Vitro (Vivo) Potent (IVP)- This compound has been designated as a potential toxin based upon preclinical data from the National Cancer Institute screening program

[REDACTED]

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 259968

CAS: 64755-14-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

12. Ecological Information

The ecological impact of this material is not yet known.

13. Disposal Considerations

Disposal

Observe all Federal, state, and local laws concerning the disposal of hazardous material or waste.

EPA Hazardous Waste Number

14. Transportation Information

Shipping of samples of this material should adhere to current regulations.

UN 2811, TOXIC SOLID, ORGANIC, N.O.S., (BOUVARDIN), 6.1, III

15. Regulatory Information

All Federal, state, and local regulations should be observed.

16. Other Information

Disclaimer

The information in this document was compiled primarily from secondary sources. The information is believed to be correct and accurate, but no independent verification has been performed. No warranty is expressed or implied with respect to the information contained herein.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 259969

CAS: 64725-24-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

1. Company Identification

In Case of Emergency Call:

Decontamination Procedures	Pharmaceutical Resources Branch,(301)-496-8780
Material Safety Data Sheets	Drug Synthesis and Chemistry Branch,(301)-496-8795
Toxicity Data	Toxicology Branch,(301)-496-8777
Additional Information	

2. Chemical Product and Composition

Chemical Name	BOUVARDIN, 5-(N-METHYL-L-TYROSINE)- (9CI)
Common Name	DEOXYBOUVARDIN
Synonyms	
Molecular Weight	757
Molecular Formula	C40H48N6O9
Composition	This material consists solely of 259969
Additional Information	

3. Hazards Identification

RTECS Index	
Summary of Risks	To the best of our knowledge, the toxicological properties of this material have not yet been fully investigated.
Known Carcinogen	This compound is not listed in the OSHA, IARC or NTP literature as a carcinogen or cancer suspect agent.
Medical Conditions Aggravated by Contact	Unknown
Target Organs	The target organs of toxicity are not known at this time.
Relevant Routes of Entry	Inhalation, ingestion, and skin/eye contact.
Acute Effects	The acute effects of exposure to this material in the workplace are not known at this time.
Chronic Effects	The chronic effects of exposure to this material in the workplace are not known at this time.
Eye Contact	The effects of eye contact with this material are unknown.
Skin Contact	The effects of skin contact with this material are unknown.
Inhalation	The effects of inhalation of this material are unknown.
Ingestion	The effects of ingestion of this material are unknown.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 259969

CAS: 64725-24-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

Known Hazards

TOX IVP

Additional Information

Toxic (TOX) - Avoid all contact. Use proper engineering controls and personal protective equipment when handling.

4. First Aid Measures

Eye Contact Flush with running water for at least 15 minutes. Assure adequate flushing by separating eyelids with fingers. Consult an ophthalmologist immediately.

Skin Contact Remove contaminated clothing. Flush exposed area with running water for at least 15 minutes. Wash skin with plenty of soap and water. Consult a physician. Chemically decontaminate clothing and launder before reuse.

Inhalation Remove victim promptly to fresh air. Administer artificial respiration if victim is not breathing. If breathing is difficult give oxygen. Consult a physician.

Ingestion If person is conscious wash out mouth with water to remove residual compound. Consult a physician immediately.

Additional Provide supportive treatment. No specific antidote exists.

5. Fire Fighting Measures

LEL Unknown Flash Point Unknown

UEL Unknown Auto Ignition Temp Unknown

Extinguishing Media Water, carbon dioxide, or dry chemical as appropriate to the surrounding fire.

Explosion Hazard Explosive characteristics of this material are not known to have been investigated.

Special Procedures Evacuate personnel to a safe area. Fire fighters should use protective clothing and a self-contained breathing apparatus. Follow DOT emergency guide number 53 f or solids (or 55 for liquids)(1991 Emergency Response Guidebook, DOT P 5800.5).

Hazardous Combustion Byproducts Thermal decomposition may produce toxic by-products or fumes such as carbon monoxide and carbon dioxide and nitrogen oxides. Since specific products of combustion are unknown, as a precaution, assume they are hazardous.

Additional Information

6. Accidental Release Measures

Evacuate the area. Wear a respirator (or if properly trained, a self-contained breathing apparatus), rubber boots, and heavy rubber gloves. Wear disposable coveralls and discard after use. Avoid raising aerosols by promptly covering the spilled compound with wet paper towels. Pick up material with additional towels, place in a bag or barrel, and hold for waste disposal. After compound pick-up is complete, ventilate area and wash spill site.

Developmental Therapeutics Program, National Cancer Institute
 Executive Plaza North, Room 831
 6130 Executive Blvd., Rockville, MD 20852

NSC: 259969
 CAS: 64725-24-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
 Last Revised: 11/18/1997 1:59:54 PM

Dispose of contaminated clean-up materials properly.

7. Handling and Storage

Special Handling

This material is an investigational substance. Hazards associated with exposure to this material are unknown. Handling of solids or solutions should be carried out with extreme care to avoid personal exposure. This material should be handled only by those trained in the handling of potentially hazardous material.

Special Storage

Freeze (FRZ) between -18 and -22 degrees Celcius

Additional Information

Wash thoroughly after handling.

8. Exposure Controls and Personal Protection

Goggles

Wear chemical safety goggles when handling this material.

Gloves

Wear rubber or latex gloves (not polyvinylchloride) when handling this material. Laboratory coat or apron and sleeves are also recommended.

Respirator

Wear a NIOSH-MSHA approved respirator. Supplied-air packs could alternatively be used by personnel trained in the use of this equipment.

Safety Station

Safety shower and eye wash should be accessible.

Apparel

Wear a protective laboratory coat or a Tyvek suit with shoe covers during bulk operations.

Ventillation

Operations should be conducted in a chemical fume hood, glove box, or ventilated cabinet equipped with mechanical exhaust to the outside. General room ventilation should meet good laboratory design standards.

Additional Information

The personal protective equipment listed above should be worn when handling this material. Consider engineering and operational controls to minimize exposure potential.

9. Physical and Chemical Properties

Characteristics

Unknown

Additional Information

10. Stability and Reactivity

Chemical Stability

This material is stable under most conditions. Hazardous polymerization is not known to occur.

11. Toxicological Information

In-Vitro (Vivo) Potent (IVP)- This compound has been designated as a potential toxin based upon preclinical data from the National Cancer Institute screening program

Developmental Therapeutics Program, National Cancer Institute
Executive Plaza North, Room 831
6130 Executive Blvd., Rockville, MD 20852

NSC: 259969
CAS: 64725-24-2

Supplier MSDS N

Create Date: 6/28/1995 7:46:48 AM
Last Revised: 11/18/1997 1:59:54 PM

12. Ecological Information

The ecological impact of this material is not yet known.

13. Disposal Considerations

Disposal

Observe all Federal, state, and local laws concerning the disposal of hazardous material or waste.

EPA Hazardous Waste Number

14. Transportation Information

Shipping of samples of this material should adhere to current regulations.

UN 2811, TOXIC SOLID, ORGANIC, N.O.S., (DEOXYBOUVARDIN), 6.1, III

15. Regulatory Information

All Federal, state, and local regulations should be observed.

16. Other Information

Disclaimer

The information in this document was compiled primarily from secondary sources. The information is believed to be correct and accurate, but no independent verification has been performed. No warranty is expressed or implied with respect to the information contained herein.

FAX COVER SHEET

SAIC / Frederick
P.O. Box B
Frederick, Maryland 21702

Date: May 7, 2007
To: Scott Keimig
Location: bdy 426
Phone # _____
Fax # 6619

FROM: IN VIVO CARCINOGENESIS PROGRAM
BUILDING 539 3RD FLOOR
FREDERICK, MARYLAND 21702
PHONE # (301) 846-1270
FAX # (301) 846-1293

NUMBER OF PAGES INCLUDING COVER SHEET: lots

MESSAGE: Scott - Final 7 MSDS from
Reilly's protocol 06-018 M4 which I need
for Jutp
Thanks Aid

CONFIDENTIALITY NOTICE

"WARNING" Unauthorized interception of this telephonic communication could be a violation of Federal and Maryland Law. The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for return of the original document to us.